Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
<h4>Purpose</h4>To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).<h4>Methods</h4>This study included 93 eyes of 90 patients. The incidence of em...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0259879 |